Another limitation of this study was the impossibility to include studies that assessed the effects of exercise among BCP during neoadjuvant therapy, or among patients with BC related long-term side effects (e.g. lymphedema and aromatase inhibitor arthralgia). Here, CYP19A1 is linked to lymphedema.